866-997-4948(US-Canada Toll Free)

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Diseases & Conditions

No. of Pages : 42 Pages

Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014

Summary

Global Markets Directs, Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infectionss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview 7
Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis 8
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies 9
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 10
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance 11
Early Stage Products 11
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies 12
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 13
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development 14
Galapagos NV 14
Arsanis Biosciences GmbH 15
TherimuneX Pharamaceuticals, Inc. 16
Ruthigen, Inc. 17
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
GLPG-1492 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
acALY18 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
(hypochlorous acid + magnesium) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ASN-100 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gamma AApeptides - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates 35
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects 36
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products 37
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Product Development Milestones 38
Featured News & Press Releases 38
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 38
Jan 07, 2013: New compound overcomes drug-resistant Staph infection in mice 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Table

List of Tables
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2014 7
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Products under Investigation by Universities/Institutes, H1 2014 13
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2014 14
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Arsanis Biosciences GmbH, H1 2014 15
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by TherimuneX Pharamaceuticals, Inc., H1 2014 16
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Ruthigen, Inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Assessment by Combination Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2014 35
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects, H1 2014 36
Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products, H1 2014 37

List of Chart

List of Figures
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2014 7
Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H1 2014 8
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *